TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE

• THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO

  UEI C3KXNLTAAY98 · not in the directory yet

  $1.2M

  Subcontractor to this prime · 3 sub-awards · latest Jun 9, 2026

  • National Institutes of Health
  • “MAINTAIN THE WEB-BASED DATA ENTRY SYSTEM FOR USE BY RURAL MEU AND RELEVANT STUDY CORES TO ENTER COLLECTED EXAM-RELATED DATA (COMPLETING THE ONGOING BASELINE EXAMINATION TO REACH ENROLLMENT OF 4600 PARTICIPANTS ACROSS ALL 10 COUNTIES -MONITOR DATA COLLECTION -PROVIDE MONTHLY QUALITY CONTROL REPORTS TO THE QC COMMITTEE AND THE STEERING COMMITTEE -MAINTAIN WEB-BASED DASHBOARD OF PARTICIPATION -MAINTAIN LOGS OF EDIT CHECK AND IDENTIFIED ERRORS; PURSUE MISSING DATA AND CORRECTABLE ERRORS BY COMMUNICATION WITH MEU AND RELEVANT STUDY CORES WITHIN THREE WEEKS OF RECEIPT AND REVIEW OF DATA; DEVELOP, MAINTAIN, AND MODIFY AN AUDIT TRAIL FOR ALL DATA TRANSFER AND DATA CORRECTION ACTIVITIES -PREPARE AND MAKE AVAILABLE AN INTERIM AND FINAL EXAM 1 DATASET”
  • “-CONTRIBUTE TO STUDY MANAGEMENT THROUGH SERVICE ON THE STEERING COMMITTEE AND SUBCOMMITTEES -SUBMIT BIANNUAL REPORT TO THE CONTRACTOR, INCLUDING AREA OF RESPONSIBILITY, STAFF ROLES, AND FTE ACTIVITIES PERFORMANCE ISSUES -ESTABLISH AND MAINTAIN ALL STUDY DATABASES (EXAMINATIONS AND INTERVIEWS, FOLLOW-UP DATA, IMAGING MEASUREMENTS AND RESULTS, LABORATORY MEASUREMENTS, MORBIDITY AND MORTALITY DATA, AND THOSE FROM ALL SUB-STUDIES AND ANCILLARY STUDIES, INCLUDING IMAGES) -MAINTAIN AND UPDATE AS NEEDED A SECTION 508-COMPLIANT RURAL WEB-BASED DATA ENTRY AND MANAGEMENT SYSTEM -MAINTAIN A DATABASE ON INFORMED CONSENT VERSIONS AND PARTICIPANT RESPONSES COVERING EXAM 1 AND IF CONDUCTED, EXAM 2 -MAINTAIN DATA ON QC MEASUREMENTS -MAINTAIN A REPOSITORY FOR IMAGING STUDIES -PREPARE NHLBI DATA REPOSITORY DATA SETS AND DOCUMENTATION FOR SUBMISSION TO THE BIODATA CATALYST (BDC) -DEVELOP, UPDATE, AND IMPLEMENT AN INFORMATION SYSTEMS SECURITY PLAN -MANAGE EXECUTION OF AND MAINTAIN DATA DISTRIBUTION AGREEMENTS AND DATA AND MATERIALS DISTRIBUTION AGREEMENTS”
  • “-UPDATE AND MAINTAIN SYSTEMS TO PERFORM EXAM 2 OPERATIONS WITH SIMILAR SPECIFICATIONS AS TO THOSE UNDER B.1 (N=4,000 PARTICIPANTS) -PROVIDE MONTHLY QUALITY CONTROL REPORTS TO QA/QC COMMITTEE AND STEERING COMMITTEE -MAINTAIN LOGS OF EDIT CHECKS CONDUCTED AND IDENTIFIED ERRORS; CORRECT ERRORS BY COMMUNICATION WITH MEU AND RELEVANT STUDY CORES WITHIN THREE WEEKS OF RECEIPT AND REVIEW OF DATA -COMPLETE DATA CLEANING AND RESOLUTION OF MISSING AND ERRONEOUS VALUES -PREPARE AND MAKE AVAILABLE AN INTERIM AND FINAL EXAM 2 DATASET”
• TRIAD NATIONAL SECURITY, LLC

  UEI X7WUS5LRBQU3

  $1M

  Subcontractor to this prime · 1 sub-award · latest Jun 16, 2025

  • Department of Energy
  • “UNIVERSITY OF PENNSYLVANIA-STAND ALONE-ITEM LEVEL-R AND D”
• ST JUDE CHILDREN'S RESEARCH HOSPITAL INC

  UEI JL4JHE9SDRR3

  $744.4K

  Subcontractor to this prime · 1 sub-award · latest Jul 29, 2024

  • National Institutes of Health
  • “OPTION 17A/B: UPENN BIOINFORMATIC RESOURCES FOR AI EVOLUTION (MONCLA) (MOD 16)”
• AUBURN UNIVERSITY

  UEI DMQNDJDHTDG4

  $250.4K

  Subcontractor to this prime · 1 sub-award · latest Mar 26, 2026

  • Office of Procurement Operations
  • “DETECTION CANINE APPLIED RESEARCH & DEVELOPMENT”
• EMORY UNIVERSITY

  UEI S352L5PJLMP8

  $202.2K

  Subcontractor to this prime · 1 sub-award · latest May 8, 2026

  • National Institutes of Health
  • “EMORY CEIRR”
• CALIFORNIA INSTITUTE OF TECHNOLOGY

  UEI U2JMKHNS5TG4

  $80K

  Subcontractor to this prime · 1 sub-award · latest Jan 6, 2026

  • Defense Advanced Research Projects Agency
  • “OPTIMIZING CONCEPT, TOPOLOGY AND DESIGN FOR NOVEL ULTRALIGHT PRECISION STRUCTURES”

• REGENTS OF THE UNIVERSITY OF MICHIGAN

  UEI GNJ7BBP73WE9 · not in the directory yet

  $2.3M

  Subcontracted by this company · 2 sub-awards · latest Apr 22, 2026

  • National Institutes of Health
  • “LONGITUDINAL HUMAN INFLUENZA STUDIES: THE UNIVERSITY OF MICHIGAN TEAM WILL CONDUCT A LONGITUDINAL HUMAN COHORT STUDY OVER THE PROJECT PERIOD. THIS COHORT WILL INCLUDE SURVEILLANCE FOR INFLUENZA AND OTHER INFECTIOUS DISEASES AND PERIODIC BLOOD SPECIMENS TO SUPPORT IMMUNOLOGIC STUDIES. THE UNIVERSITY OF MICHIGAN TEAM WILL ENROLL SUBJECTS, MANAGE SUBJECT INCENTIVES, COLLECT INTERVIEW AND SURVEY DATA, COLLECT HEALTH RECORD AND VACCINE REGISTRY DATA, COLLECT AND STORE NASAL SPECIMENS, CONDUCT VIRAL SAMPLING AND TESTING AND PROCESS AND STORE BLOOD SPECIMENS. THE UNIVERSITY OF MICHIGAN TEAM WILL ALSO HANDLE IRB AND DATA MANAGEMENT FOR THE HIVE COHORT. INFLUENZA SURVEILLANCE, RISK ASSESSMENT, AND RESPONSE: THE UNIVERSITY OF MICHIGAN TEAM WILL SEQUENCE A SELECTION OF INFLUENZA VIRUSES OBTAINED FROM THE LOCAL HUMAN LONGITUDINAL COHORT AND PROVIDE THAT DATA TO THE CENTER TO INFORM INFLUENZA SURVEILLANCE AND RESPONSE. PATHOGENESIS AND IMMUNE RESPONSE RESEARCH: THE UNIVERSITY OF MICHIGAN TEAM WILL USE THE SPECIMENS AND DATA COLLECTED AS PART OF THE LONGITUDINAL HUMAN INFLUENZA STUDIES TO CONDUCT EVALUATIONS OF RESPONSES TO INFECTION AND VACCINATION, CORRELATES OF PROTECTION, AND PREDICTORS OF TRANSMISSION (PROJECT 1). THE TEAM WILL ADDITIONALLY CONDUCT EVALUATIONS OF INTRAHOST DIVERSITY AND VIRAL EVOLUTION (PROJECT 3). AS PART OF THIS WORK, THE UNIVERSITY OF MICHIGAN TEAM WILL COLLECT SERIAL VIRAL SAMPLES IN COHORT PARTICIPANTS AND WILL CONDUCT ANTIBODY TESTING ON BLOOD SPECIMENS. THE UNIVERSITY OF MICHIGAN TEAM WILL MANAGE DATA AND CONDUCT STATISTICAL ANALYSES FOR THE PROPOSED OBJECTIVES.”
  • “SUBJECT INCENTIVES WILL BE PROVIDED AT THE ENROLLMENT, ILLNESS VISIT, AND BLOOD DRAW VISITS. THE SPECIFIC BREAKDOWN OF INCENTIVE COSTS IS AS FOLLOWS:  ENROLLMENT AND ANNUAL RE-ENGAGEMENT VISITS FOR INDIVIDUALS CONTRIBUTING SPECIMENS TO PROPOSED ANALYSES. ESTIMATED INCENTIVE IS $10 PER INDIVIDUAL FOR 1,400 INDIVIDUALS EACH YEAR FOR A TOTAL COST OF $14,000 ANNUALLY.  STUDY SITE ILLNESS VISITS FOR SPECIMEN COLLECTION TO SUPPORT LABORATORY CONFIRMATION OF INFLUENZA ILLNESS. ESTIMATED INCENTIVE IS $15 PER VISIT FOR 1,200 ILLNESS VISITS EACH YEAR FOR A TOTAL COST OF $18,000 ANNUALLY.  BLOOD COLLECTION VISITS ARE ANTICIPATED FOR THE FOLLOWING: 550 PARTICIPANTS 2 TIMES PER YEAR (1100 TOTAL) AND A 7-DAY POST-VACCINATION COLLECTION IN 250 VACCINATED INDIVIDUALS, FOR A TOTAL OF 1,350 COLLECTIONS. ESTIMATED INCENTIVE IS $20 PER VISIT FOR A TOTAL COST OF $27,000 ANNUALLY. INCENTIVE PAYMENT AMOUNTS ARE BASED UPON AMOUNTS PROVIDED IN PAST SUCCESSFUL STUDIES.”
• FRED HUTCHINSON CANCER CENTER

  UEI TJFZLPP6NYL6

  $1.5M

  Subcontracted by this company · 4 sub-awards · latest May 20, 2026

  • National Institutes of Health
  • “BLOOM LAB THE BLOOM LAB WILL PERFORM EXPERIMENTAL AND COMPUTATIONAL WORK TO CHARACTERIZE INFLUENZA VIRUS EVOLUTION. IN PROJECT 3, THEY WILL USE MUTATIONAL ANTIGENIC PROFILING TO EXPERIMENTALLY MAP THE EFFECTS OF VIRAL MUTATIONS ON IMMUNE RECOGNITION. BEDFORD LAB THE BEDFORD LAB AT THE FRED HUTCH WILL BE RESPONSIBLE FOR IMPLEMENTATION OF PROJECT 3, AIM 2 (PREDICT AND VISUALIZE WHICH CIRCULATING CLADES OF INFLUENZA WILL DOMINATE USING PHYLOGENETIC ANALYSES, AGE-STRUCTURED SEROLOGY, MUTATIONAL ANTIGENIC PROFILING, AND VACCINATION COVERAGE). FOR THIS, THE BEDFORD LAB WILL DEVELOP AND IMPLEMENT A PREDICTIVE MODEL THAT INCORPORATES DATA GENERATED BY THE BLOOM LAB FOR PROJECT 3, AIM 1 AS WELL AS OTHER SEROLOGICAL DATA GENERATED BY THE CENTER. THE BEDFORD LAB WILL INTEGRATE THIS SEROLOGICAL DATA WITH PUBLICLY AVAILABLE INFLUENZA GENETIC SEQUENCE DATA. THIS MODEL WILL ESTIMATE THE EVOLUTIONARY TRAJECTORY OF THE INFLUENZA VIRUS POPULATION.”
  • “3. STATEMENT OF WORK 1. SCOPE: THE UNIVERSITY OF PENNSYLVANIA CENTER OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE (PENN-CEIRR) BRINGS TOGETHER RENOWNED RESEARCHERS AND CUTTING-EDGE TECHNOLOGIES TO DISCOVER NEW INFORMATION AND TOOLS NEEDED TO DECREASE THE MORTALITY AND MORBIDITY ASSOCIATED WITH INFLUENZA VIRUSES AND OTHER PATHOGENS. 2. TECHNICAL REQUIREMENTS. INDEPENDENTLY, AND NOT AS AN AGENT OF THE GOVERNMENT, THE CONTRACTOR SHALL FURNISH ALL NECESSARY SERVICES, QUALIFIED PROFESSIONAL, TECHNICAL, AND ADMINISTRATIVE PERSONNEL, MATERIAL, EQUIPMENT AND FACILITIES, NOT OTHERWISE PROVIDED BY THE GOVERNMENT UNDER THE TERMS OF THIS CONTRACT, AS NEEDED TO PERFORM THE TASKS SET FORTH BELOW. SPECIFICALLY, THE CONTRACTOR SHALL:”
  • “3. STATEMENT OF WORK 1. SCOPE: THE UNIVERSITY OF PENNSYLVANIA CENTER OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE (PENN-CEIRR) BRINGS TOGETHER RENOWNED RESEARCHERS AND CUTTING-EDGE TECHNOLOGIES TO DISCOVER NEW INFORMATION AND TOOLS NEEDED TO DECREASE THE MORTALITY AND MORBIDITY ASSOCIATED WITH INFLUENZA VIRUSES AND OTHER PATHOGENS. 2. TECHNICAL REQUIREMENTS. INDEPENDENTLY, AND NOT AS AN AGENT OF THE GOVERNMENT, THE CONTRACTOR SHALL FURNISH ALL NECESSARY SERVICES, QUALIFIED PROFESSIONAL, TECHNICAL, AND ADMINISTRATIVE PERSONNEL, MATERIAL, EQUIPMENT AND FACILITIES, NOT OTHERWISE PROVIDED BY THE GOVERNMENT UNDER THE TERMS OF THIS CONTRACT, AS NEEDED TO PERFORM THE TASKS SET FORTH BELOW. SPECIFICALLY, THE CONTRACTOR SHALL:”
• AGRICULTURAL RESEARCH SERVICE

  UEI KB99WN8JF8K9 · not in the directory yet

  $1.5M

  Subcontracted by this company · 4 sub-awards · latest Jul 21, 2026

  • National Institutes of Health
  • “RESEARCH SUBCONTRACT ATTACHMENT 4 SUBCONTRACTOR STATEMENT OF WORK AND REPORTING REQUIREMENTS REPORTING - "SERVICE CONTRACT REPORTING REQUIREMENTS" (HTTPS://WWW.ACQUISITION.GOV/ FAR/52.204-14 A) FOR THE PERIOD OF PERFORMANCE 4/01/2026 TO 9/21/2027, THE FOLLOWING INFORMATION MUST BE REPORTED TO THE PRIME AUTHORIZED OFFICIAL BY 10/1/2027. 1) SUBCONTRACTOR NAME 2) SUBCONTRACTOR DUNS NUMBER 3) SUBCONTRACTOR NUMBER, AN 4) SUBCONTRACTOR DIRECT LABOR HOURS THIS INFORMATION WILL BE MADE AVAILABLE TO THE PUBLIC AS REQUIRED BY SECTION 743 OF DIVISION C OF THE CONSOLIDATED APPROPRIATIONS ACT, 2010 NOTE: SEE PRIME AGREEMENT FOR SAMPLE INVOIC THE USDA WILL TRANSPORT COWS FROM PENNSYLVANIA TO IOWA AND THEN CHALLENGE THE ANIMALS WITH H5N1 UNDER BSL3 CONDITIONS. CLINICAL SIGNS, MILK PRODUCTION AND CONSISTENCY, AND OTHER PARAMETERS WILL BE RECORDED AFTER H5N1 CHALLENGE. TISSUE SECTIONS WILL BE MADE AFTER THE ANIMALS ARE EUTHANIZED AT THE END OF THE EXPERIMENT. OVER THE COURSE OF THIS PROJECT, THE USDA WILL COMPLETE 2 OF THESE EXPERIMENTS, WITH 4 ANIMALS PER EACH EXPERIMENT. THE SECOND EXPERIMENT WILL ONLY BE CONDUCTED IF THE 1ST EXPERIMENT IS SUCCESSFUL.”
  • “STATEMENT OF WORK – PROJECT 3 OBJECTIVES. WE WILL TARGET HUMAN-SWINE INTERFACES IN MAJOR SWINE PRODUCTION REGIONS IN THE US, EUROPE, AND ASIA. COORDINATED SURVEILLANCE WITH SWINE AND HUMAN SAMPLE COLLECTION THAT LEVERAGES EXISTING SURVEILLANCE [E.G., US DEPARTMENT OF AGRICULTURE (USDA) NATIONAL IAV IN SWINE (IAV-S) SURVEILLANCE SYSTEM AND VETERINARY DIAGNOSTIC LABS] WILL ALLOW US TO QUANTIFY DRIVERS OF IAV EVOLUTION IN THE SWINE HOST. OUR OVERALL OBJECTIVE IS TO DEVELOP A RISK FRAMEWORK THAT ARTICULATES HOW ANTIGENIC DIVERSITY AND OTHER PHENOTYPIC PROPERTIES OF CIRCULATING SWINE IAVS AFFECT HUMAN PANDEMIC POTENTIAL AND INTERSPECIES TRANSMISSION. WE WILL DETERMINE THE PUBLIC HEALTH RISK OF CIRCULATING AND EMERGING IAVS IN GLOBAL SWINE POPULATIONS BY A COORDINATED AND SYSTEMATIC PIPELINE OF IN SILICO, IN VITRO, AND IN VIVO TESTING AND ANALYSES. SWINE IAV ISOLATES IDENTIFIED AS UNIQUE THROUGH SURVEILLANCE AND IN VIVO ANALYSES WILL BE CHARACTERIZED BY A IN VIVO AND IN VITRO PANDEMIC POTENTIAL PIPELINE AMONG CEIRR INVESTIGATORS. APPROACH. THIS OBJECTIVE WILL BE ACCOMPLISHED WITH 4 STREAMS OF SWINE VIROLOGIC DATA: 1) ACTIVE SURVEILLANCE IN CAMBODIA; 2) ACTIVE AND PASSIVE SURVEILLANCE IN THE UK; 3) ACTIVE AND PASSIVE SURVEILLANCE IN THE USA; AND 4) LEVERAGING THE USDA SURVEILLANCE SYSTEM AND ESTABLISHED SWINE INFLUENZA NETWORKS. HUMAN SAMPLING WILL OCCUR AT THE SWINE INTERFACE IN CAMBODIA AND THE USA. SEROLOGIC SPECIMENS WILL BE USED FROM OCCUPATIONALLY EXPOSED HUMAN COHORTS TO EVALUATE ANTIBODY RESPONSES TO SWINE IAV AND COMPARE TO URBAN HUMAN COHORTS. SEQUENCE ANALYSIS OF IAV-S WILL BE SUPPORTED BY DEDICATED SWINE COMPUTATIONAL EXPERTISE AND ANTIGENIC AND PHENOTYPIC CHARACTERIZATION OF SWINE IAV FOR ASSESSMENT OF RISK TO HUMANS CONDUCTED IN AND IN VIVO AND IN VITRO PANDEMIC POTENTIAL PIPELINE. EACH OF THESE COMPONENTS WILL CONTRIBUTE TO DEVELOPMENT OF A RISK RANKING METHOD FOR SWINE IAV. METHODS. AIM 1. INVESTIGATE DYNAMICS OF IAV AT HUMAN-SWINE INTE”
  • “STATEMENT OF WORK – PROJECT 3 OBJECTIVES. WE WILL TARGET HUMAN-SWINE INTERFACES IN MAJOR SWINE PRODUCTION REGIONS IN THE US, EUROPE, AND ASIA. COORDINATED SURVEILLANCE WITH SWINE AND HUMAN SAMPLE COLLECTION THAT LEVERAGES EXISTING SURVEILLANCE [E.G., US DEPARTMENT OF AGRICULTURE (USDA) NATIONAL IAV IN SWINE (IAV-S) SURVEILLANCE SYSTEM AND VETERINARY DIAGNOSTIC LABS] WILL ALLOW US TO QUANTIFY DRIVERS OF IAV EVOLUTION IN THE SWINE HOST. OUR OVERALL OBJECTIVE IS TO DEVELOP A RISK FRAMEWORK THAT ARTICULATES HOW ANTIGENIC DIVERSITY AND OTHER PHENOTYPIC PROPERTIES OF CIRCULATING SWINE IAVS AFFECT HUMAN PANDEMIC POTENTIAL AND INTERSPECIES TRANSMISSION. WE WILL DETERMINE THE PUBLIC HEALTH RISK OF CIRCULATING AND EMERGING IAVS IN GLOBAL SWINE POPULATIONS BY A COORDINATED AND SYSTEMATIC PIPELINE OF IN SILICO, IN VITRO, AND IN VIVO TESTING AND ANALYSES. SWINE IAV ISOLATES IDENTIFIED AS UNIQUE THROUGH SURVEILLANCE AND IN VIVO ANALYSES WILL BE CHARACTERIZED BY A IN VIVO AND IN VITRO PANDEMIC POTENTIAL PIPELINE AMONG CEIRR INVESTIGATORS. APPROACH. THIS OBJECTIVE WILL BE ACCOMPLISHED WITH 4 STREAMS OF SWINE VIROLOGIC DATA: 1) ACTIVE SURVEILLANCE IN CAMBODIA; 2) ACTIVE AND PASSIVE SURVEILLANCE IN THE UK; 3) ACTIVE AND PASSIVE SURVEILLANCE IN THE USA; AND 4) LEVERAGING THE USDA SURVEILLANCE SYSTEM AND ESTABLISHED SWINE INFLUENZA NETWORKS. HUMAN SAMPLING WILL OCCUR AT THE SWINE INTERFACE IN CAMBODIA AND THE USA. SEROLOGIC SPECIMENS WILL BE USED FROM OCCUPATIONALLY EXPOSED HUMAN COHORTS TO EVALUATE ANTIBODY RESPONSES TO SWINE IAV AND COMPARE TO URBAN HUMAN COHORTS. SEQUENCE ANALYSIS OF IAV-S WILL BE SUPPORTED BY DEDICATED SWINE COMPUTATIONAL EXPERTISE AND ANTIGENIC AND PHENOTYPIC CHARACTERIZATION OF SWINE IAV FOR ASSESSMENT OF RISK TO HUMANS CONDUCTED IN AND IN VIVO AND IN VITRO PANDEMIC POTENTIAL PIPELINE. EACH OF THESE COMPONENTS WILL CONTRIBUTE TO DEVELOPMENT OF A RISK RANKING METHOD FOR SWINE IAV. METHODS. AIM 1. INVESTIGATE DYNAMICS OF IAV AT HUMAN-SWINE INTERFACES THROUGH: A) LO”
• THE ROYAL VETERINARY COLLEGE

  UEI CUV4KZ1VZKK5 · not in the directory yet

  $949.2K

  Subcontracted by this company · 2 sub-awards · latest Jun 24, 2026

  • National Institutes of Health
  • “STATEMENT OF WORK THE ROYAL VETERINARY COLLEGE WILL COMPLETE AN AVIAN INFLUENZA VIRUS SURVEILLANCE PROJECT INVOLVING THE COLLECTION OF APPROXIMATELY 2,300 AVIAN OROPHARYNGEAL AND CLOACAL SWABS FROM LIVE BIRD MARKETS AND FARMS IN CHATTOGRAM, BANGLADESH, WHICH IS CONDUCTED BY CVASU, AND 1,018 HUMAN NASAL AND THROAT SWABS AND 237 HUMAN BLOOD SAMPLES FROM INDIVIDUALS LIVING IN CHATTOGRAM, BANGLADESH, WHICH IS CONDUCTED BY IEDCR. THEY WILL DEVELOP A RISK FRAMEWORK THAT DETERMINES HOW ANTIGENIC DIVERSITY AND OTHER PHENOTYPIC PROPERTIES OF CIRCULATING AVIAN INFLUENZA VIRUSES AFFECT HUMAN PANDEMIC POTENTIAL AND INTERSPECIES TRANSMISSION. THE ROYAL VETERINARY COLLEGE WILL PARTICIPATE IN PANDEMIC RESPONSE RESEARCH THAT WILL INCLUDE FULL CHARACTERIZATIONS OF BOTH AVIAN AND SWINE INFLUENZA VIRUSES. THE ROYAL VETERINARY COLLEGE WILL OVERSEE AND WORK DIRECTLY WITH PERSONNEL IN, BANGLADESH (IEDCR AND CVASU), THE FRANCIS CRICK TRADING LTD AND THE APHA TO ACCOMPLISH THESE GOALS. THE ROYAL VETERINARY COLLEGE WILL PARTICIPATE IN PANDEMIC RESPONSE RESEARCH THAT WILL INCLUDE FULL CHARACTERIZATIONS OF BOTH AVIAN AND SWINE INFLUENZA VIRUSES. THE ROYAL VETERINARY COLLEGE WILL OVERSEE AND WORK DIRECTLY WITH PERSONNEL IN, BANGLADESH, THE FRANCIS CRICK TRADING LTD AND THE APHA TO ACCOMPLISH THESE GOALS.”
  • “THE ROYAL VET COLLEGE WILL COMPLETE A SWINE INFLUENZA VIRUS SURVEILLANCE PROJECT INVOLVING THE COLLECTION OF APPROXIMATELY 4,800 SWINE NASAL SWABS FROM CAMBODIA, 1,200 HUMAN SERUM AND WHOLE BLOOD SAMPLES FROM CAMBODIA, THROAT SWABS FROM SYMPTOMATICALLY INFECTED HUMANS IN CAMBODIA, AND 2,290 SWINE RESPIRATORY SAMPLES FROM THE UK AND EU. THEY WILL DEVELOP A RISK FRAMEWORK THAT DETERMINES HOW ANTIGENIC DIVERSITY AND OTHER PHENOTYPIC PROPERTIES OF CIRCULATING SWINE INFLUENZA VIRUSES AFFECT HUMAN PANDEMIC POTENTIAL AND INTERSPECIES TRANSMISSION. THE ROYAL VET COLLEGE WILL COMPLETE AN AVIAN INFLUENZA VIRUS SURVEILLANCE PROJECT INVOLVING THE COLLECTION OF APPROXIMATELY 2,300 AVIAN OROPHARYNGEAL AND CLOACAL SWABS FROM LIVE BIRD MARKETS AND FARMS IN CHATTOGRAM, BANGLADESH, AND 1,018 HUMAN NASAL AND THROAT SWABS AND 237 HUMAN BLOOD SAMPLES FROM INDIVIDUALS LIVING IN CHATTOGRAM, BANGLADESH. THEY WILL DEVELOP A RISK FRAMEWORK THAT DETERMINES HOW ANTIGENIC DIVERSITY AND OTHER PHENOTYPIC PROPERTIES OF CIRCULATING AVIAN INFLUENZA VIRUSES AFFECT HUMAN PANDEMIC POTENTIAL AND INTERSPECIES TRANSMISSION. THE ROYAL VET COLLEGE WILL PARTICIPATE IN PANDEMIC RESPONSE RESEARCH THAT WILL INCLUDE FULL CHARACTERIZATIONS OF BOTH AVIAN AND SWINE INFLUENZA VIRUSES. THE ROYAL VET COLLEGE WILL OVERSEE AND WORK DIRECTLY WITH PERSONNEL IN CAMBODIA, BANGLADESH, AND THE APHA TO ACCOMPLISH THESE GOALS.”
• UNIVERSITY OF HONG KONG, THE

  UEI F7RGJJCNHMA4 · not in the directory yet

  $919.3K

  Subcontracted by this company · 2 sub-awards · latest May 28, 2026

  • National Institutes of Health
  • “SCOPE OF WORK I WILL ESTABLISH AND FOLLOW-UP A COHORT OF AT LEAST 1000 INDIVIDUALS OF ALL AGES IN AT LEAST 400 HOUSEHOLDS IN HONG KONG. BLOOD WILL BE COLLECTED AT LEAST TWICE A YEAR FROM EVERY INDIVIDUAL, AND PARTICIPANTS WILL BE ACTIVELY MONITORED DURING INFLUENZA SEASONS FOR ACUTE RESPIRATORY ILLNESSES SO THAT WE CAN COLLECT RESPIRATORY SAMPLES FOR PCR CONFIRMATION OF INFLUENZA VIRUS INFECTIONS. A SUBSET OF THE PCR-POSITIVE SAMPLES WILL BE SEQUENCED. IN ADDITION, I WILL CONTRIBUTE TO ANALYSIS AND INTERPRETATION OF DATA ON RATES OF INFECTION OVER TIME, IMMUNE CORRELATES OF PROTECTION IN INDIVIDUALS, AND I WILL WORK WITH CO-PI COBEY ON MODELING CHANGES IN POPULATION IMMUNITY OVER TIME RESULTING FROM THE USE OF INFLUENZA VACCINES AS WELL AS INFLUENZA EPIDEMICS IN THE POPULATION.”
  • “SCOPE OF WORK I WILL ESTABLISH AND FOLLOW‐UP A COHORT OF AT LEAST 1000 INDIVIDUALS OF ALL AGES IN AT LEAST 400 HOUSEHOLDS IN HONG KONG. BLOOD WILL BE COLLECTED AT LEAST TWICE A YEAR FROM EVERY INDIVIDUAL, AND PARTICIPANTS WILL BE ACTIVELY MONITORED DURING INFLUENZA SEASONS FOR ACUTE RESPIRATORY ILLNESSES SO THAT WE CAN COLLECT RESPIRATORY SAMPLES FOR PCR CONFIRMATION OF INFLUENZA VIRUS INFECTIONS. A SUBSET OF THE PCR‐POSITIVE SAMPLES WILL BE SEQUENCED. IN ADDITION, I WILL CONTRIBUTE TO ANALYSIS AND INTERPRETATION OF DATA ON RATES OF INFECTION OVER TIME, IMMUNE CORRELATES OF PROTECTION IN INDIVIDUALS, AND I WILL WORK WITH CO‐PI COBEY ON MODELING CHANGES IN POPULATION IMMUNITY OVER TIME RESULTING FROM THE USE OF INFLUENZA VACCINES AS WELL AS INFLUENZA EPIDEMICS IN THE POPULATION.”
• SCRIPPS RESEARCH INSTITUTE

  UEI PHZJFZ32NKH4

  $912.7K

  Subcontracted by this company · 2 sub-awards · latest Apr 6, 2026

  • National Institutes of Health
  • “IN THIS PROJECT, WE WILL STRUCTURALLY AND BIOPHYSICALLY CHARACTERIZE NEUTRALIZING ANTIBODIES AND IMMUNE SERA DERIVED FROM NATURAL INFECTION BY INFLUENZA VIRUS AND FROM VACCINATION. THE WILSON LAB WILL EXPRESS AND PURIFY ANTIBODIES, ANTIGENS AND IMMUNOGENS FROM MAMMALIAN CELL LINES, INCLUDING 293S, 293T AND 293F CELLS, DROSOPHILA CELLS, OR E. COLI FOR STRUCTURAL AND BIOPHYSICAL STUDIES. WE WILL THEN STRUCTURALLY AND BIOPHYSICALLY ANALYZE THESE NEUTRALIZING ANTIBODIES WITH INFLUENZA ANTIGENS [HEMAGGLUTININ (HA), AND NEURAMINIDASE (NA)], AS WELL AS IDENTIFIED RESISTANCE MUTANTS, TO DETERMINE ANTIBODY AFFINITIES AND MODE OF BINDING, STABILITY, STOICHIOMETRY, EPITOPES AND 3D STRUCTURES. WE WILL USE X-RAY CRYSTALLOGRAPHY TO DETERMINE THE HIGH-RESOLUTION STRUCTURES OF ANTIBODIES AND ANTIBODY-ANTIGEN COMPLEXES. OTHER BIOPHYSICAL METHODS INCLUDING BIO-LAYER INTERFEROMETRY (BLI), ISOTHERMAL TITRATION CALORIMETRY ITC), DIFFERENTIAL SCANNING CALORIMETRY (DSC) AND SURFACE PLASMON RESONANCE (SPR), WILL BE USED TO DETERMINE BINDING AFFINITIES AND PROTEIN/IMMUNOGEN STABILITY. WE WILL DESIGN, MODIFY AND CHARACTERIZE IMMUNOGENS AS VACCINES CANDIDATES USING STRUCTURE-ASSISTED VACCINE DESIGN METHODS THAT WE HAVE PREVIOUSLY SUCCESSFULLY UTILIZED FOR HIV, INFLUENZA VIRUS AND HEPATITIS C VIRUS. THE WARD LAB WILL UTILIZE THEIR RECENTLY DEVELOPED NOVEL EM IMAGING METHOD OF POLYCLONAL EPITOPE MAPPING (EMPEM) TO ANALYZE POLYCLONAL ANTIBODY RESPONSES IN SERA TO IDENTIFY PATTERNS OF EPITOPE UTILIZATION AND FREQUENCY IN HA AND NA IN HUMAN LONGITUDINAL COHORTS. THE HA OR NA PROTEIN PROBES IN THESE ANALYSES WILL BE PRODUCED IN THE WILSON LAB AND SERA PROVIDED BY OUR COLLEAGUES IN THIS CEIRR PROJECT.”
  • “STATEMENT OF WORK FOR WILSON AND WARD LABS IN THIS PROJECT, WE WILL STRUCTURALLY AND BIOPHYSICALLY CHARACTERIZE NEUTRALIZING ANTIBODIES AND IMMUNE SERA DERIVED FROM NATURAL INFECTION BY INFLUENZA VIRUS AND FROM VACCINATION. THE WILSON LAB WILL EXPRESS AND PURIFY ANTIBODIES, ANTIGENS AND IMMUNOGENS FROM MAMMALIAN CELL LINES, INCLUDING 293S, 293T AND 293F CELLS, DROSOPHILA CELLS, OR E. COLI FOR STRUCTURAL AND BIOPHYSICAL STUDIES. WE WILL THEN STRUCTURALLY AND BIOPHYSICALLY ANALYZE THESE NEUTRALIZING ANTIBODIES WITH INFLUENZA ANTIGENS [HEMAGGLUTININ (HA), AND NEURAMINIDASE (NA)], AS WELL AS IDENTIFIED RESISTANCE MUTANTS, TO DETERMINE ANTIBODY AFFINITIES AND MODE OF BINDING, STABILITY, STOICHIOMETRY, EPITOPES AND 3D STRUCTURES. WE WILL USE X-RAY CRYSTALLOGRAPHY TO DETERMINE THE HIGH-RESOLUTION STRUCTURES OF ANTIBODIES AND ANTIBODY-ANTIGEN COMPLEXES. OTHER BIOPHYSICAL METHODS INCLUDING BIO-LAYER INTERFEROMETRY (BLI), ISOTHERMAL TITRATION CALORIMETRY ITC), DIFFERENTIAL SCANNING CALORIMETRY (DSC) AND SURFACE PLASMON RESONANCE (SPR), WILL BE USED TO DETERMINE BINDING AFFINITIES AND PROTEIN/IMMUNOGEN STABILITY. WE WILL DESIGN, MODIFY AND CHARACTERIZE IMMUNOGENS AS VACCINES CANDIDATES USING STRUCTURE-ASSISTED VACCINE DESIGN METHODS THAT WE HAVE PREVIOUSLY SUCCESSFULLY UTILIZED FOR HIV, INFLUENZA VIRUS AND HEPATITIS C VIRUS. THE WARD LAB WILL UTILIZE THEIR RECENTLY DEVELOPED NOVEL EM IMAGING METHOD OF POLYCLONAL EPITOPE MAPPING (EMPEM) TO ANALYZE POLYCLONAL ANTIBODY RESPONSES IN SERA TO IDENTIFY PATTERNS OF EPITOPE UTILIZATION AND FREQUENCY IN HA AND NA IN HUMAN LONGITUDINAL COHORTS. THE HA OR NA PROTEIN PROBES IN THESE ANALYSES WILL BE PRODUCED IN THE WILSON LAB AND SERA PROVIDED BY OUR COLLEAGUES IN THIS CEIRR PROJECT.”
• THE UNIVERSITY OF CHICAGO

  UEI ZUE9HKT2CLC9

  $861.8K

  Subcontracted by this company · 3 sub-awards · latest Apr 9, 2026

  • National Institutes of Health
  • “DR.COBEY WILL LEAD THE LONGITUDINAL, EPIDEMIOLOGICAL, AND EVOLUTIONARY MODELING AS PART OF THE "PATHOGENESIS AND IMMUNE RESPONSE RESEARCH” COMPONENT, PROJECTS 1 AND 3. IN PROJECT 1,HER GROUP WILL DEVELOP INDIVIDUAL, LONGITUDINAL MODELS TO UNDERSTAND THE DEVELOPMENT OF IMMUNITY AND PROTECTION TO INFLUENZA OVER TIME, WITH A PARTICULAR FOCUS ON UNDERSTANDING THE EVOLUTION OF ANTIBODY SPECIFICITY AND CONSEQUENCES FOR PROTECTION AND TRANSMISSION. HER GROUP WILL ALSO PROVIDE BROAD STATISTICAL SUPPORT FOR THE WORK CONDUCTED IN PROJECT 1. DR.COBEY WITH CO-LEAD ALL ACTIVITIES IN PROJECT 3, WHICH FOCUSES ON PREDICTING VIRAL EVOLUTIONARY AND EPIDEMIOLOGICAL DYNAMICS ON A GLOBAL SCALE. HER GROUP WILL ALSO SUPPORT MODELING EFFORTS IN OTHER COMPONENTS OF THE CENTER, FOR INSTANCE, RELATED TO PROJECT 2 OR PANDEMIC PREPAREDNESS.”
  • “3. STATEMENT OF WORK 1. SCOPE: THE UNIVERSITY OF PENNSYLVANIA CENTER OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE (PENN-CEIRR) BRINGS TOGETHER RENOWNED RESEARCHERS AND CUTTING-EDGE TECHNOLOGIES TO DISCOVER NEW INFORMATION AND TOOLS NEEDED TO DECREASE THE MORTALITY AND MORBIDITY ASSOCIATED WITH INFLUENZA VIRUSES AND OTHER PATHOGENS. 2. TECHNICAL REQUIREMENTS. INDEPENDENTLY, AND NOT AS AN AGENT OF THE GOVERNMENT, THE CONTRACTOR SHALL FURNISH ALL NECESSARY SERVICES, QUALIFIED PROFESSIONAL, TECHNICAL, AND ADMINISTRATIVE PERSONNEL, MATERIAL, EQUIPMENT AND FACILITIES, NOT OTHERWISE PROVIDED BY THE GOVERNMENT UNDER THE TERMS OF THIS CONTRACT, AS NEEDED TO PERFORM THE TASKS SET FORTH BELOW. SPECIFICALLY, THE CONTRACTOR SHALL:”
  • “STATEMENT OF WORK MY GROUP WILL BE ENGAGED IN TWO MAJOR ACTIVITIES AS PART OF THIS CEIRR CENTER: 1. LONGITUDINAL, EPIDEMIOLOGICAL, AND EVOLUTIONARY MODELING AS PART OF THE “PATHOGENESIS AND IMMUNE RESPONSE RESEARCH” COMPONENT, PROJECTS 1 AND 3. IN PROJECT 1, WE WILL DEVELOP INDIVIDUAL, LONGITUDINAL MODELS TO UNDERSTAND THE DEVELOPMENT OF IMMUNITY AND PROTECTION TO INFLUENZA OVER TIME, WITH A PARTICULAR FOCUS ON UNDERSTANDING THE EVOLUTION OF ANTIBODY SPECIFICITY AND CONSEQUENCES FOR PROTECTION AND TRANSMISSION. WE WILL ALSO PROVIDE BROAD STATISTICAL SUPPORT FOR THE WORK CONDUCTED IN PROJECT 1. DR. COBEY WITH CO-LEAD ALL ACTIVITIES IN PROJECT 3, WHICH FOCUSES ON PREDICTING VIRAL EVOLUTIONARY AND EPIDEMIOLOGICAL DYNAMICS ON A GLOBAL SCALE. HER FOCUS WILL BE ON INTEGRATING AIMS 2 AND 3, WHICH INVOLVES FORECASTING THE DYNAMICS OF CLADES, SUBTYPES, AND TYPES USING POPULATION-LEVEL TIMES SERIES OF CASES AND IMMUNE PROFILES. THESE MODELS WILL FURTHER BE RECONCILED WITH THOSE IN PROJECT 1. 2. MY GROUP WILL LEAD THE COMPUTATIONAL CORE. THE CORE’S MAJOR ACTIVITIES WILL BE EXPANDED ANALYSES USING DATA FROM MULTIPLE CENTERS TO (1) FORECAST VIRAL EVOLUTION AND EPIDEMIOLOGY, (2) UNDERSTAND IMMUNE CORRELATES OF RISK, PROTECTION, VACCINE FAILURE, AND TRAMISSION, AND (3) ANALYZE OTHER ASPECTS OF THE IMMUNE RESPONSE TO INFLUENZA, INFLUENZA DYNAMICS, AND VACCINATION. ADDITIONALLY, WE WILL DEVELOP NOVEL BIOINFORMATIC TOOLS TO (4) INFER ANTIBODY SPECIFICITY, (5) ASSESS SELECTION USING MUTANT LIBRARIES, (6) VISUALIZE VIRAL EVOLUTION, AND (7) DEVELOP NEW ANTIGENIC MAPS GIVEN HOSTS’ COMPLEX IMMUNE HISTORIES. MY GROUP WILL COORDINATE THESE ACTIVITIES AND TAKE THE LEAD ON SEVERAL, ESPECIALLY (2), (3), (4), AND (7). IN ADDITION, WE WILL IDENTIFY MODELING OPPORTUNITIES AND COORDINATE MODELING EFFORTS BETWEEN THE CENTERS, INCREASE MODELING CAPACITY, AND ASSIST WITH STUDY DESIGN AND DATA INTEGRATION. WE WILL ALSO SUPPORT MODELING EFFORTS IN OTHER COMPONENTS OF THE CENTER, FOR INSTANCE, RELATED”
• UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  UEI MKAGLD59JRL1

  $789.1K

  Subcontracted by this company · 3 sub-awards · latest Apr 16, 2026

  • National Institutes of Health
  • “IN THIS CEIRR APPLICATION, THE LAKDAWALA LAB AT THE UNIVERSITY OF PITTSBURGH WILL LEVERAGE OUR INFLUENZA TRANSMISSION AND PATHOGENESIS EXPERTISE TO ASSIST IN MULTIPLE PROJECTS. IN ADDITION, WE USE OUR EXTENSIVE KNOWLEDGE OF VIRAL PROPERTIES THAT PROMOTE AIRBORNE TRANSMISSION OF INFLUENZA VIRUSES TO CHARACTERIZE EMERGING ZOONOTIC STRAINS EACH YEAR. OUR SPECIFIC STATEMENT OF WORK FOR EACH ELEMENT OF THE CEIRR APPLICATION IS DETAILED BELOW. REQUIRED #3: INFLUENZA SURVEILLANCE, RISK ASSESSMENT AND RESPONSE TASKS: 1. ASSESS THE REPLICATION OF EMERGING SWINE AND AVIAN VIRUSES IN PRIMARY HUMAN BRONCHIAL EPITHELIAL CELLS. 2. ASSIST IN MOLECULAR CHARACTERIZATION OF EMERGING SWINE AND AVIAN VIRUSES. REQUIRED #4: PRE-PANDEMIC AND PANDEMIC RESPONSE TASKS: 1. PERFORM FERRET PATHOGENESIS STUDIES FOR 1-3 INFLUENZA VIRUSES PER YEAR. (UP TO 12 ANIMALS PER YEAR) 2. PERFORM FERRET AIRBORNE TRANSMISSION STUDIES IN NAÏVE ANIMALS FOR 1-3 VIRUSES PER YEAR. (24 ANIMALS PER YEAR) 3. ASSESS TRANSMISSIBILITY OF EMERGING VIRUSES IN FERRETS WITH PRE-EXISTING IMMUNITY. (16 ANIMALS PER YEAR) 4. PERFORM MOLECULAR CHARACTERIZATION OF THESE VIRUSES TO ASSESS GROWTH IN PRIMARY HUMAN AIRWAY CELLS, STABILITY IN SIMULATED EXPELLED DROPLETS, RECEPTOR AND CELL TROPISM, AND NA ACTIVITY. REQUIRED #5: PATHOGENESIS AND IMMUNE RESPONSE RESEARCH (PROJECT 2: IMMUNITY CHANGING OVER TIME). TASKS: 1. PERFORM FERRET STUDIES TO ASSESS IMMUNE RESPONSES TO VACCINATION IN THE CONTEXT OF PRE-EXISTING IMMUNITY. (8 ANIMALS PER YEAR) 2. PERFORM FERRET STUDIES TO DEFINE THE LONGEVITY OF ANTIBODY RESPONSES IN THE FERRET MODEL (4 ANIMALS PER YEAR)”
  • “LE SAGE SCOPE OF WORK FOR PENN-CEIRR OPTION 18.L THIS CEIRR CONCEPT PROPOSAL HAS TWO DISTINCT AIMS THAT WILL ENABLE CHARACTERIZATION OF H5N1 HIGHLY PATHOGENIC AVIAN INFLUENZA (HPAI) VIRUS IN TERMS OF HOST AND ENVIRONMENTAL FACTORS THAT AFFECT TRANSMISSIBILITY. H5N1 HPAI STRAINS THAT ARE IMPORTANT TO THE DAIRY CATTLE OUTBREAK WILL BE ASSESS IN THE FOLLOWING AIMS. THERE ARE MANY IN VITRO CHARACTERISTICS THAT HAVE AN IMPACT ON EFFICIENT TRANSMISSION OF INFLUENZA VIRUS. IN AIM 1, I WILL CHARACTERIZE H5N1 HPAI STRAINS TO BETTER UNDERSTAND HOST TROPISM AND ENVIRONMENTAL STABILITY. THE FOLLOWING TASKS WILL BE ACCOMPLISHED: 1. EXAMINE REPLICATION KINETICS OF H5N1 HPAI IN PRIMARY HUMAN AIRWAY EPITHELIAL CELLS AND COMPARE IT TO A SEASONAL INFLUENZA VIRUS. 2. PERFORM SINGLE CELL RNA SEQUENCING ON THE INFECTED PRIMARY HUMAN AIRWAY EPITHELIAL CELLS TO COMPARE HOST TROPISM BETWEEN H5N1 HPAI AND SEASONAL INFLUENZA VIRUS. 3. COMPARE THE SECRETED CYTOKINES AND CHEMOKINES FROM H5N1 HPAI OR SEASONAL INFLUENZA VIRUS INFECTED PRIMARY HUMAN AIRWAY EPITHELIAL CELLS USING LUMINEX ASSAY. 4. DETERMINE THE ENVIRONMENTAL STABILITY UNDER A RANGE OF RELATIVE HUMIDITIES IN STATIONARY DROPLETS THAT CONTAIN MUCUS, COLLECTED FROM PRIMARY HUMAN AIRWAY EPITHELIAL CELLS. PRE-EXISTING IMMUNITY IS AN IMPORTANT BARRIER TO INFLUENZA VIRUS TRANSMISSION. IN AIM 2, I WILL ASSESS THE IMPACT OF SEASONAL VACCINATION IN FERRETS PRIOR TO CHALLENGE WITH H5N1 HPAI. THE FOLLOWING TASKS WILL BE ACCOMPLISHED: 1. PERFORM FERRET PATHOGENESIS AND SURVIVAL STUDIES IN FERRETS THAT HAVE BEEN VACCINATED WITH A SEASONAL INFLUENZA VIRUS THREE MONTHS PRIOR TO INTRANASAL CHALLENGE. 2. AS AIRBORNE TRANSMISSION IS NOT EFFICIENT FOR HPAI STRAINS, I WILL LEVERAGE THE AEROBIOLOGY CORE AT THE UNIVERSITY OF PITTSBURGH TO COMPARE THE SUSCEPTIBILITY OF VACCINATED FERRETS TO AEROSOL CHALLENGE OF H5N1 HPAI CHALLENGE. 3. PERFORM SEROLOGICAL ASSAYS TO DETERMINE THE LEVELS OF CROSS-REACTIVE HA AND NA ANTIBODIES GENERATED BY THESE VACCINATED FE”
  • “LAKDAWALA STATEMENT OF WORK IN THIS CEIRR APPLICATION, THE LAKDAWALA LAB AT THE UNIVERSITY OF PITTSBURGH WILL LEVERAGE OUR INFLUENZA TRANSMISSION AND PATHOGENESIS EXPERTISE TO ASSIST IN MULTIPLE PROJECTS. IN ADDITION, WE USE OUR EXTENSIVE KNOWLEDGE OF VIRAL PROPERTIES THAT PROMOTE AIRBORNE TRANSMISSION OF INFLUENZA VIRUSES TO CHARACTERIZE EMERGING ZOONOTIC STRAINS EACH YEAR. OUR SPECIFIC STATEMENT OF WORK FOR EACH ELEMENT OF THE CEIRR APPLICATION IS DETAILED BELOW. REQUIRED #3: INFLUENZA SURVEILLANCE, RISK ASSESSMENT AND RESPONSE TASKS: 1. ASSESS THE REPLICATION OF EMERGING SWINE AND AVIAN VIRUSES IN PRIMARY HUMAN BRONCHIAL EPITHELIAL CELLS. 2. ASSIST IN MOLECULAR CHARACTERIZATION OF EMERGING SWINE AND AVIAN VIRUSES. REQUIRED #4: PRE-PANDEMIC AND PANDEMIC RESPONSE TASKS: 1. PERFORM FERRET PATHOGENESIS STUDIES FOR 1-3 INFLUENZA VIRUSES PER YEAR. (UP TO 12 ANIMALS PER YEAR) 2. PERFORM FERRET AIRBORNE TRANSMISSION STUDIES IN NAÏVE ANIMALS FOR 1-3 VIRUSES PER YEAR. (24 ANIMALS PER YEAR) 3. ASSESS TRANSMISSIBILITY OF EMERGING VIRUSES IN FERRETS WITH PRE-EXISTING IMMUNITY. (16 ANIMALS PER YEAR) 4. PERFORM MOLECULAR CHARACTERIZATION OF THESE VIRUSES TO ASSESS GROWTH IN PRIMARY HUMAN AIRWAY CELLS, STABILITY IN SIMULATED EXPELLED DROPLETS, RECEPTOR AND CELL TROPISM, AND NA ACTIVITY. REQUIRED #5: PATHOGENESIS AND IMMUNE RESPONSE RESEARCH (PROJECT 2: IMMUNITY CHANGING OVER TIME). TASKS: 1. PERFORM FERRET STUDIES TO ASSESS IMMUNE RESPONSES TO VACCINATION IN THE CONTEXT OF PRE-EXISTING IMMUNITY. (8 ANIMALS PER YEAR) 2. PERFORM FERRET STUDIES TO DEFINE THE LONGEVITY OF ANTIBODY RESPONSES IN THE FERRET MODEL (4 ANIMALS PER YEAR)”
• THE LELAND STANFORD JUNIOR UNIVERSITY

  UEI HJD6G4D6TJY5

  $720.1K

  Subcontracted by this company · 2 sub-awards · latest May 8, 2026

  • National Institutes of Health
  • “IN THIS CONTRACT, THE BOYD LAB WILL CARRY OUT THE FOLLOWING ACTIVITIES: PROJECT 1: CREATE ANTIBODY GENE SEQUENCE LIBRARIES FROM A MICHIGAN HUMAN COHORT AND, SUBJECT TO AVAILABILITY, A HONG KONG HUMAN SUBJECT COHORT, FROM PERIPHERAL BLOOD MONONUCLEAR CELLS OF SAMPLES TAKEN DURING SURVEILLANCE FOR INFLUENZA INFECTION, OR PRIOR TO AND FOLLOWING INFLUENZA VACCINATION. THESE LIBRARIES WILL BE SEQUENCED USING THE ILLUMINA MISEQ INSTRUMENT. DATA WILL BE ANALYZED TO EVALUATE B CELL CLONAL POPULATIONS AND CANDIDATE VACCINE-RESPONSIVE B CELLS. PROJECT 2: FROM A HUMAN COHORT IN PENNSYLVANIA, CREATE ANTIBODY GENE SEQUENCE LIBRARIES FROM PERIPHERAL BLOOD MONONUCLEAR CELLS OF SAMPLES TAKEN DURING SURVEILLANCE FOR INFLUENZA INFECTION, OR PRIOR TO AND FOLLOWING INFLUENZA VACCINATION. THESE LIBRARIES WILL BE SEQUENCED USING THE ILLUMINA MISEQ INSTRUMENT. DATA WILL BE ANALYZED TO EVALUATE B CELL CLONAL POPULATIONS AND CANDIDATE VACCINE-RESPONSIVE B CELLS. IN ADDITION, INFLUENZASPECIFIC B CELLS WILL BE ISOLATED BY FLOW CYTOMETRIC SORTING FOLLOWING INFLUENZA VACCINATION, AND SINGLE-CELL PCR WILL BE CARRIED OUT TO AMPLIFY ANTIBODY HEAVY AND LIGHT CHAINS. WE WILL THEN SEQUENCE THOSE PCR AMPLICONS AND CLONE THEM INTO EXPRESSION VECTORS FOR GENERATION OF MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES WILL BE SHARED WITH OTHER PROJECT INVESTIGATORS FOR CHARACTERIZATION FOR BINDING TO INFLUENZA VACCINE COMPONENTS IN ELISA ASSAYS AND WITH HEMAGGLUTININ INHIBITION ASSAYS. WE WILL ANALYZE THE ANTIBODY GENE SEQUENCE DATA AND CORRELATE IT WITH THE BINDING AND OTHER PROTEIN ASSAY DATA FROM THE MONOCLONAL ANTIBODIES GENERATED. IN ADDITION WE WILL SEQUENCE ANTIBODY GENE LIBRARIES GENERATED FROM FERRETS IN THIS PROJECT, AND ATTEMPT TO CLONE THE HEAVY AND LIGHT CHAIN GENE SEQUENCES FROM FERRET CELLS THAT BIND INFLUENZA ANTIGENS, TO EXPRESS THE ANTIBODIES AS PROTEIN FOR FURTHER CHARACTERIZATION BY OTHER PROJECT INVESTIGATORS. WE WILL ANALYZE THE FERRET ANTIBODY GENE SEQUENCE DATA BY COMPARING THEM TO THE”
  • “SCOPE OF WORK IN THIS CONTRACT, THE BOYD LAB WILL CARRY OUT THE FOLLOWING ACTIVITIES: PROJECT 1: CREATE ANTIBODY GENE SEQUENCE LIBRARIES FROM A MICHIGAN HUMAN COHORT AND, SUBJECT TO AVAILABILITY, A HONG KONG HUMAN SUBJECT COHORT, FROM PERIPHERAL BLOOD MONONUCLEAR CELLS OF SAMPLES TAKEN DURING SURVEILLANCE FOR INFLUENZA INFECTION, OR PRIOR TO AND FOLLOWING INFLUENZA VACCINATION. THESE LIBRARIES WILL BE SEQUENCED USING THE ILLUMINA MISEQ INSTRUMENT. DATA WILL BE ANALYZED TO EVALUATE B CELL CLONAL POPULATIONS AND CANDIDATE VACCINE-RESPONSIVE B CELLS. PROJECT 2: FROM A HUMAN COHORT IN PENNSYLVANIA, CREATE ANTIBODY GENE SEQUENCE LIBRARIES FROM PERIPHERAL BLOOD MONONUCLEAR CELLS OF SAMPLES TAKEN DURING SURVEILLANCE FOR INFLUENZA INFECTION, OR PRIOR TO AND FOLLOWING INFLUENZA VACCINATION. THESE LIBRARIES WILL BE SEQUENCED USING THE ILLUMINA MISEQ INSTRUMENT. DATA WILL BE ANALYZED TO EVALUATE B CELL CLONAL POPULATIONS AND CANDIDATE VACCINE-RESPONSIVE B CELLS. IN ADDITION, INFLUENZASPECIFIC B CELLS WILL BE ISOLATED BY FLOW CYTOMETRIC SORTING FOLLOWING INFLUENZA VACCINATION, AND SINGLE-CELL PCR WILL BE CARRIED OUT TO AMPLIFY ANTIBODY HEAVY AND LIGHT CHAINS. WE WILL THEN SEQUENCE THOSE PCR AMPLICONS AND CLONE THEM INTO EXPRESSION VECTORS FOR GENERATION OF MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES WILL BE SHARED WITH OTHER PROJECT INVESTIGATORS FOR CHARACTERIZATION FOR BINDING TO INFLUENZA VACCINE COMPONENTS IN ELISA ASSAYS AND WITH HEMAGGLUTININ INHIBITION ASSAYS. WE WILL ANALYZE THE ANTIBODY GENE SEQUENCE DATA AND CORRELATE IT WITH THE BINDING AND OTHER PROTEIN ASSAY DATA FROM THE MONOCLONAL ANTIBODIES GENERATED. IN ADDITION WE WILL SEQUENCE ANTIBODY GENE LIBRARIES GENERATED FROM FERRETS IN THIS PROJECT, AND ATTEMPT TO CLONE THE HEAVY AND LIGHT CHAIN GENE SEQUENCES FROM FERRET CELLS THAT BIND INFLUENZA ANTIGENS, TO EXPRESS THE ANTIBODIES AS PROTEIN FOR FURTHER CHARACTERIZATION BY OTHER PROJECT INVESTIGATORS. WE WILL ANALYZE THE FERRET ANTIBODY GENE SEQUENCE DATA BY COMPARI”
• EMORY UNIVERSITY

  UEI S352L5PJLMP8

  $718.2K

  Subcontracted by this company · 2 sub-awards · latest Apr 1, 2026

  • National Institutes of Health
  • “LAKDAWALA STATEMENT OF WORK IN THIS REVISED CEIRR SUBCONTRACT, THE LAKDAWALA LAB AT EMORY UNIVERSITY WILL LEVERAGE OUR INFLUENZA TRANSMISSION AND PATHOGENESIS EXPERTISE TO ASSIST IN MULTIPLE PROJECTS. WE USE OUR EXTENSIVE KNOWLEDGE OF VIRAL PROPERTIES THAT PROMOTE AIRBORNE TRANSMISSION OF INFLUENZA VIRUSES TO CHARACTERIZE EMERGING ZOONOTIC STRAINS EACH YEAR. OUR SPECIFIC STATEMENT OF WORK FOR EACH ELEMENT OF THE CEIRR APPLICATION IS DETAILED BELOW. REQUIRED #3: INFLUENZA SURVEILLANCE, RISK ASSESSMENT AND RESPONSE TASKS: 1. ASSESS THE REPLICATION OF EMERGING SWINE AND AVIAN VIRUSES IN PRIMARY HUMAN BRONCHIAL EPITHELIAL CELLS. 2. ASSIST IN MOLECULAR CHARACTERIZATION OF EMERGING SWINE AND AVIAN VIRUSES. REQUIRED #4: PRE-PANDEMIC AND PANDEMIC RESPONSE TASKS: 1. PERFORM FERRET PATHOGENESIS STUDIES FOR 1-3 INFLUENZA VIRUSES PER YEAR. (UP TO 12 ANIMALS PER YEAR) 2. PERFORM FERRET AIRBORNE TRANSMISSION STUDIES IN NAÏVE ANIMALS FOR 1-3 VIRUSES PER YEAR. (24 ANIMALS PER YEAR) 3. ASSESS TRANSMISSIBILITY OF EMERGING VIRUSES IN FERRETS WITH PRE-EXISTING IMMUNITY. (16 ANIMALS PER YEAR) 4. PERFORM MOLECULAR CHARACTERIZATION OF THESE VIRUSES TO ASSESS GROWTH IN PRIMARY HUMAN AIRWAY CELLS, STABILITY IN SIMULATED EXPELLED DROPLETS, RECEPTOR AND CELL TROPISM, AND NA ACTIVITY. REQUIRED #5: PATHOGENESIS AND IMMUNE RESPONSE RESEARCH (PROJECT 2: IMMUNITY CHANGING OVER TIME). TASKS: 1. PERFORM FERRET STUDIES TO ASSESS IMMUNE RESPONSES TO VACCINATION IN THE CONTEXT OF PRE-EXISTING IMMUNITY. (8 ANIMALS PER YEAR) 2. PERFORM FERRET STUDIES TO DEFINE THE LONGEVITY OF ANTIBODY RESPONSES IN THE FERRET MODEL (4 ANIMALS PER YEAR)”
• THE CHARLES STARK DRAPER LABORATORY, INC.

  UEI GTJHZE4M7YK1

  $499.1K

  Subcontracted by this company · 1 sub-award · latest Jan 3, 2025

  • Department of the Air Force
  • “DARPA/I2OS COMPARTMENTALIZATION AND PRIVILEGE MANAGEMENT, CPM, PROGRAMS FOCUS IS ON SECURING THE VULNERABLE LEGACY CODE BASE. COMPLEMENTARY SOFTWARE AND HARDWARE SOLUTIONS ARE SOUGHT THAT WILL MAKE IT ECONOMICALLY VIABLE TO COMPARTMENTALIZE LEGACY SOFTWARE AROUND LEAST- PRIVILEGE PRINCIPLES WHILE ALSO DEMONSTRATING A HARDWARE ROADMAP THAT ENABLES PERFORMANT IMPLEMENTATION. CPM IS PARTITIONED INTO THREE TECHNICAL AREAS (TAS): 1) AUTOMATED COMPARTMENTALIZATION, 2) PRIVILEGE POLICY ENFORCEMENT, AND 3) EVALUATION SUPPORT. A NEW SOLICITATION FOR A FOURTH TECHNICAL AREA, TA4: DOD SYSTEM EXPERIMENTATION, IS ANTICIPATED PRIOR TO PHASE 2, AFTER THE PROGRAM IS WELL UNDERWAY. TA1 PERFORMERS WILL DEVELOP SOFTWARE ANALYSIS TOOLS THAT AUTOMATICALLY RESTRUCTURE LEGACY SOFTWARE SYSTEMS. THE RESTRUCTURED SYSTEM SHOULD CONTAIN FINE-GRAINED COMPARTMENTS AND ACCESS CONTROL RULES THAT LIMIT PRIVILEGES TO JUST THOSE NEEDED TO PERFORM THEIR TASK. THE RESTRUCTURED SYSTEM WILL ALSO RESTRICT THE TRANSITIONS BETWEEN EXECUTION CONTEXTS (I.E., PRINCIPALS) TO ONLY THOSE NEEDED. TA2 PERFORMERS SHOULD DEVELOP PROCESSOR ARCHITECTURES AND SYSTEM SOFTWARE THAT WILL, WITH LOW OVERHEAD, ENFORCE COMPARTMENT AND PRIVILEGE MANAGEMENT PROTOCOLS DISCOVERED BY TA1 TOOLS TO PREVENT INITIAL PENETRATIONS FROM PROPAGATING INTO SUCCESSFUL CYBER-ATTACKS. CPM IS PLANNED AS A 48-MONTH PROGRAM WITH A 30-MONTH PHASE 1 AND AN 18-MONTH PHASE 2. PHASE 1 WILL FOCUS ON TECHNOLOGY DEVELOPMENT, SPECIFICALLY USING A UNIX-LIKE OS SUCH AS LINUX AS THE TEST AND EVALUATION SUITE. PHASE 2 WILL FOCUS ON SCALING THE TECHNOLOGIES AND WILL ADD USER- SPACE PROGRAMS TO THE TEST AND EVALUATION SUITE. MORE DETAILED BACKGROUND REGARDING CPM GOALS AND REQUIREMENTS ARE PROVIDED IN DARPA/I2O BAA #HR0011-23-S-0028, AMENDMENT 1, DATED 13-APR-2023. THE CHARLES STARK DRAPER LABORATORY, INC. (DRAPER) PREVIOUSLY DEVELOPED THE PROCESSOR INTERLOCKS FOR POLICY ENFORCEMENT (PIPE) ARCHITECTURE THAT IMPLEMENTS SOME O”
• UNIVERSITY OF MARYLAND BALTIMORE COUNTY

  UEI RNKYWXURFRL5 · not in the directory yet

  $377.2K

  Subcontracted by this company · 1 sub-award · latest Apr 9, 2025

  • National Institutes of Health
  • “STATEMENT OF WORK PI: MAƩHEW FRIEMAN UNIVERSITY OF MARYLAND, BALƟMORE PENN CEIRR OPƟON 18.L SEPTEMBER 11, 2024 IN THESE STUDIES, WE WILL DEVELOP AND USE A NOVEL PHAGE DISPLAY CORONAVIRUS SPIKE LIBRARY, SPIKE-SCAN, TO DETERMINE HOW VACCINE PLATFORM, FORMULATION OR COMBINATION SCHEME AƯECTS EPITOPE PRESENTATION. WE HYPOTHESIZE THAT THE DEVELOPMENT OF THIS DATA WILL AID IN OUR FUTURE VACCINE DEVELOPMENT TO DETERMINE HOW EACH OF THESE PARAMETERS AƯECTS EPITOPE SPREAD AND ULTIMATELY FUTURE PROOFING OF VACCINES. THIS NEW “SPIKE-SCAN” PLATFORM WILL BE USED TO ASSESS ANTIBODIES PRODUCED ACROSS MULTIPLE VACCINE PLATFORMS INCLUDING VARIANT SPIKE PROTEINS, NOVEL ADJUVANTS AND HUMAN MIX AND MATCH VACCINE STUDIES CONTROLLED CLINICAL TRIALS TO DETERMINE HOW VACCINE PLATFORM AND FORMULATION AƯECTS BREADTH OF COVERAGE. THE SPIKE-SCAN RESULTS COMBINED WITH TRADITIONAL ELISA AND NEUTRALIZATION STUDIES WILL BE USED TO INFORM FUTURE VACCINE DEVELOPMENT TO PRODUCE WIDER BREADTH AND QUANTIFIABLY HIGHER ANTIBODY RESPONSES. OUR GOAL IS TO DETERMINE AN OPTIMIZED COMBINATION OF ANTIGEN, ADJUVANT AND PLATFORM FOR FUTURE VACCINE DEVELOPMENT FOR CORONAVIRUSES. IN THIS PROJECT WE WILL FIRST PRODUCE A SPIKE DIRECTED CORONAVIRUS “SPIKE-SCAN” LIBRARY THAT INCLUDES ANIMAL AND HUMAN CORONAVIRUS SPIKE PROTEINS INCLUDING CURRENT SARS-COV-2 VARIANT SPIKE SEQUENCES. WE HAVE IDENTIFIED A BROAD SPECTRUM OF SPIKE PROTEINS ACROSS CORONAVIRUS LINEAGES THAT WILL ALLOW FOR DEEP PROFILING OF SERA FROM VACCINE STUDIES. UPON SUCCESSFUL CREATION OF THE SPIKE-SCAN LIBRARY, WE WILL ANALYZE SERUM FROM THE FOLLOWING SUBSETS: 1. NOVAVAX VARIANT SPIKE VACCINES, INCLUDING MULTIPLE SARS-COV-2 VARIANT SPIKES 2. HEXAPRO-WU1 SPIKE WITH VARIOUS ADJUVANTS TO EVALUATE CHANGES IN BREADTH OF COVERAGE 3. IMPRINTING MODELS TO ASSESS IMPACT OF PREVIOUS EXPOSURE 4. MIX AND MATCH VACCINE PLATFORMS (MRNA, ADENOVIRUS AND PROTEIN) FROM HUMAN TRIAL PATIENTS THIS WORK CAN ALSO BE APPLIED IN THE FUTURE TOWARD OTHER VACCINES INCLUDING INFLUEN”
• UNIVERSITY OF ARIZONA

  UEI ED44Y3W6P7B9 · not in the directory yet

  $376.4K

  Subcontracted by this company · 2 sub-awards · latest Apr 16, 2026

  • National Institutes of Health
  • “SUBCONTRACTOR (UNIVERSITY OF ARIZONA) – SCOPE OF WORK THE UNIVERSITY OF ARIZONA WILL CHARACTERIZE A SELECTION OF INFLUENZA VIRUSES AND OTHER PATHOGENS WITH PANDEMIC POTENTIAL USING A SUITE OF ASSAYS THAT WILL PROVIDE INSIGHTS INTO PROPERTIES THAT MAY CONTRIBUTE TO THEIR ABILITY TO SPREAD AND CAUSE DISEASE IN THE EVENT OF AN OUTBREAK. STUDIES INCLUDE BUT ARE NOT LIMITED TO ANTIGENIC ANALYSES, BIOCHEMICAL ANALYSES, AND IN VITRO EXPERIMENTS, IMMUNOLOGICAL STUDIES, GENETIC STUDIES, THERAPEUTIC STUDIES, AND OTHER STUDIES THAT INCREASE OUR KNOWLEDGE OF THE PRE-PANDEMIC AND PANDEMIC POTENTIAL OF DIFFERENT PATHOGENS.”
  • “UNIVERSITY OF ARIZONA – SCOPE OF WORK THE UNIVERSITY OF ARIZONA WILL PERFORM ANALYSES OF GENE SEQUENCES OF POTENTIAL PRE-PANDEMIC OR PANDEMIC INFLUENZA A VIRUS GENOMES TO TEST FOR GENETIC MAKERS OF VIRULENCE AND TEST POTENTIAL PRE-PANDEMIC OR PANDEMIC INFLUENZA A VIRUS STRAINS FOR SUSCEPTIBILITY TO THERAPEUTIC AGENTS.”
• IOWA STATE UNIVERSITY OF SCIENCE AND TECHNOLOGY

  UEI DQDBM7FGJPC5 · not in the directory yet

  $331.2K

  Subcontracted by this company · 2 sub-awards · latest Apr 9, 2026

  • National Institutes of Health
  • “IOWA STATE UNIVERSITY SCOPE OF WORK THIS IS A 7 YEAR PROJECT INVOLVING SURVEILLANCE FOR INFLUENZA A VIRUS IN SWINE. SAMPLING WILL OCCUR ON BOTH PIGS AND HUMANS. WE WILL IDENTIFY AND TARGET UP TO 4 BREEDING/FARROWING AND NURSERY SWINE FARMS EVERY YEAR FOR MONTHLY SAMPLE COLLECTION. THE FARMS WILL HAVE A HISTORY OR KNOWN STATUS OF INFLUENZA A INFECTION OR OUTBREAKS IN THE PIGS. AT EACH FARM, WE WILL COLLECT, 32 NASAL SWABS, 10 UDDER WIPES, 4 ORAL FLUIDS, 7 HUMAN NASAL MUCOUS WIPES, AND ONE VETERINARIAN NASAL MUCOUS WIPE. ONCE PER YEAR, A PHLEBOTOMIST WILL COLLECT A HUMAN SERUM SAMPLE, WHICH WILL INCLUDE 32 SERA FROM THE 4 PRODUCTION SYSTEMS AND 50 VETERINARIAN SERA AT A MAJOR SWINE MEETING. THE HUMAN SUBJECTS WILL ALSO ANSWER AN INFLUENZA RELATED QUESTIONNAIRE PROVIDED BY ISU. ALL SAMPLES WILL BE TESTED VIA PCR FOR INFLUENZA H1 & H3. VIRUS ISOLATION WILL BE ATTEMPTED ON POSITIVE SAMPLES. ALL TESTING WILL OCCUR IN THE LABORATORY OF THE PRIMARY INVESTIGATOR (GAUGER) OR THROUGH THE ISU VDL. THE ULTIMATE GOAL IS TO ISOLATE AN AVERAGE OF 4 INFLUENZA A VIRUSES OR MORE PER MONTH (336 OVER THE 7 YEAR PERIOD). THESE SAMPLES WILL BE SHARED WITH THE UNITED STATES DEPARTMENT OF AGRICULTURE (USDA) FOR FURTHER CHARACTERIZATION AND TESTING.”
  • “THIS IS A 7 YEAR PROJECT INVOLVING SURVEILLANCE FOR INFLUENZA A VIRUS IN SWINE. SAMPLING WILL OCCUR ON BOTH PIGS AND HUMANS. WE WILL IDENTIFY AND TARGET UP TO 4 BREEDING/FARROWING AND NURSERY SWINE FARMS EVERY YEAR FOR MONTHLY SAMPLE COLLECTION. THE FARMS WILL HAVE A HISTORY OR KNOWN STATUS OF INFLUENZA A INFECTION OR OUTBREAKS IN THE PIGS. AT EACH FARM, WE WILL COLLECT, 32 NASAL SWABS,10 UDDER WIPES, 4 ORAL FLUIDS, 7 HUMAN NASAL MUCOUS WIPES, AND ONE VETERINARIAN NASAL MUCOUS WIPE. ONCE PER YEAR, A PHLEBOTOMIST WILL COLLECT A HUMAN SERUM SAMPLE, WHICH WILL INCLUDE 32 SERA FROM THE 4 PRODUCTION SYSTEMS AND 50 VETERINARIAN SERA AT A MAJOR SWINE MEETING. THE HUMAN SUBJECTS WILL ALSO ANSWER AN INFLUENZA RELATED QUESTIONNAIRE PROVIDED BY ISU. ALL SAMPLES WILL BE TESTED VIA PCR FOR INFLUENZA H1 & H3. VIRUS ISOLATION WILL BE ATTEMPTED ON POSITIVE SAMPLES. ALL TESTING WILL OCCUR IN THE LABORATORY OF THE PRIMARY INVESTIGATOR (GAUGER) OR THROUGH THE ISU VDL. THE ULTIMATE GOAL IS TO ISOLATE AN AVERAGE OF 4 INFLUENZA A VIRUSES OR MORE PER MONTH (336 OVER THE 7 YEAR PERIOD). THESE SAMPLES WILL BE SHARED WITH THE UNITED STATES DEPARTMENT OF AGRICULTURE (USDA) FOR FURTHER CHARACTERIZATION AND TESTING.”
• NMC, INC.

  UEI TUMCX1C2C4B3

  $227.4K

  Subcontracted by this company · 1 sub-award · latest Feb 3, 2026

  • National Institutes of Health
  • “3. STATEMENT OF WORK 1. SCOPE: THE UNIVERSITY OF PENNSYLVANIA CENTER OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE (PENN-CEIRR) BRINGS TOGETHER RENOWNED RESEARCHERS AND CUTTING-EDGE TECHNOLOGIES TO DISCOVER NEW INFORMATION AND TOOLS NEEDED TO DECREASE THE MORTALITY AND MORBIDITY ASSOCIATED WITH INFLUENZA VIRUSES AND OTHER PATHOGENS. 2. TECHNICAL REQUIREMENTS. INDEPENDENTLY, AND NOT AS AN AGENT OF THE GOVERNMENT, THE CONTRACTOR SHALL FURNISH ALL NECESSARY SERVICES, QUALIFIED PROFESSIONAL, TECHNICAL, AND ADMINISTRATIVE PERSONNEL, MATERIAL, EQUIPMENT AND FACILITIES, NOT OTHERWISE PROVIDED BY THE GOVERNMENT UNDER THE TERMS OF THIS CONTRACT, AS NEEDED TO PERFORM THE TASKS SET FORTH BELOW. SPECIFICALLY, THE CONTRACTOR SHALL:”

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.